Medicare Wastage Rebate Exceptions For Small Volume Products, Cell/Gene Therapy Urged
Executive Summary
Packaging for such products reflects ‘unique circumstances’ that should exempt them from the rebates on discarded drugs otherwise required by the policy, stakeholders tell CMS at a ‘town hall’ forum.
You may also be interested in...
US Medicare Wastage ‘Refund’ Collections Delayed To ‘Align’ With IRA
A new Medicare rebate for discarded portions of single-use vials is taking effect as scheduled in January – but the first invoices won’t be issued in the fall as planned. CMS says it wants to wait to ‘align’ the collections process with the new inflation rebates enacted by the IRA.
Medicare Rebates On Drug ‘Wastage’: New Products Get Limited Time Reprieve
Regulation from CMS may drive manufacturers to repackage Medicare Part B drugs sold in single-use containers to avoid waste that would be subject to new rebate.
PBM Reforms: House Hearing Suggests Bipartisan Consensus On Legislative Policies Has Limits
There was lots of criticism of pharmacy benefit managers (and a fair amount of pharmaceutical manufacturers) at the oversight hearing. However, Democrats may be more cautious about preserving the benefits PBMs provide versus the downsides in developing reforms.